PriceTargets.com logo

OTCMKTS:DSRLF - DiaSorin Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $201.25
  • Forecasted Upside: 63.97 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$122.74 As of 05/16/2022 01:00 AM ET
▲ +7.656 (6.65%)

This chart shows the closing price for DSRLF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New DiaSorin Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DSRLF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DSRLF

Analyst Price Target is $201.25
▲ +63.97% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for DiaSorin in the last 3 months. The average price target is $201.25, with a high forecast of $201.25 and a low forecast of $201.25. The average price target represents a 63.97% upside from the last price of $122.74.

This chart shows the closing price for DSRLF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 polled investment analysts is to hold stock in DiaSorin. This rating has held steady since November 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/22/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
2/20/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
5/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 2 sell ratings
Ratings as of
8/19/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
11/17/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/15/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
4/16/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
5/16/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/23/2022Jefferies Financial GroupUpgradeUnderperform ➝ Hold
11/17/2021CheuvreuxDowngradeBuy ➝ Hold
11/17/2021Kepler Capital MarketsDowngradeBuy ➝ Hold
7/27/2021Morgan StanleyInitiated CoverageEqual Weight$201.25
6/11/2021Berenberg BankUpgradeHold ➝ Buy
3/24/2021Berenberg BankReiterated RatingHold
3/18/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight
12/10/2020BNP ParibasReiterated RatingUnderperform
12/10/2020Exane BNP ParibasReiterated RatingUnderperform
12/10/2020Kepler Capital MarketsUpgradeHold ➝ Buy
12/9/2020Morgan StanleyInitiated CoverageEqual Weight
10/30/2020Berenberg BankReiterated RatingHold
6/4/2020Berenberg BankReiterated RatingHold
5/26/2020Jefferies Financial GroupDowngradeHold ➝ Underperform
3/17/2020Berenberg BankReiterated RatingHold
(Data available from 5/17/2017 forward)

News Sentiment Rating

0.22 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/17/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/16/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/18/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/17/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/17/2022

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
DiaSorin logo
DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.
Read More

Today's Range

Now: $122.74
Low: $122.74
High: $122.74

50 Day Range

MA: $137.39
Low: $115.08
High: $152.60

52 Week Range

Now: $122.74
Low: $0.01
High: $238.29

Volume

182 shs

Average Volume

17 shs

Market Capitalization

$6.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.54

Frequently Asked Questions

What sell-side analysts currently cover shares of DiaSorin?

The following Wall Street sell-side analysts have issued research reports on DiaSorin in the last year: Berenberg Bank, Cheuvreux, Jefferies Financial Group Inc., Kepler Capital Markets, Morgan Stanley, and Zacks Investment Research.
View the latest analyst ratings for DSRLF.

What is the current price target for DiaSorin?

1 Wall Street analysts have set twelve-month price targets for DiaSorin in the last year. Their average twelve-month price target is $201.25, suggesting a possible upside of 64.0%. Morgan Stanley has the highest price target set, predicting DSRLF will reach $201.25 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $201.25 for DiaSorin in the next year.
View the latest price targets for DSRLF.

What is the current consensus analyst rating for DiaSorin?

DiaSorin currently has 4 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DSRLF, but not buy more shares or sell existing shares.
View the latest ratings for DSRLF.

How do I contact DiaSorin's investor relations team?

DiaSorin's physical mailing address is Via Crescentino, Saluggia L6, 13040. The company's listed phone number is 391614871 and its investor relations email address is [email protected] The official website for DiaSorin is www.diasoringroup.com. Learn More about contacing DiaSorin investor relations.